Healthpeak initiated with an Equal Weight at Wells Fargo

Wells Fargo initiated coverage of Healthpeak with an Equal Weight rating and $23 price target. While the firm appreciates the long-term potential of Healthpeak’s life science portfolio, it is being kept on the sidelines for now due to current inflation and interest rate dynamics in conjunction with concerns related to the Life Science space, the analyst tells investors in a research note.